List of Excipients in Branded Drug LYTGOBI

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
TAIHO PHARMACEUTICAL CO LTD	LYTGOBI	futibatinib	64842-0120	CELLULOSE, MICROCRYSTALLINE	2029-09-30
TAIHO PHARMACEUTICAL CO LTD	LYTGOBI	futibatinib	64842-0120	CROSPOVIDONE	2029-09-30
TAIHO PHARMACEUTICAL CO LTD	LYTGOBI	futibatinib	64842-0120	HYDROXYPROPYL CELLULOSE	2029-09-30
TAIHO PHARMACEUTICAL CO LTD	LYTGOBI	futibatinib	64842-0120	HYPROMELLOSE	2029-09-30
TAIHO PHARMACEUTICAL CO LTD	LYTGOBI	futibatinib	64842-0120	LACTOSE MONOHYDRATE	2029-09-30

LYTGOBI (Futibatinib) Excipient Strategy and Commercial Opportunities

Last updated: August 21, 2026

LYTGOBI (futibatinib) is an oral, irreversible FGFR1-4 inhibitor marketed by Taiho Oncology for previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma with an FGFR2 fusion or rearrangement. Its current tablet excipient system is conventional and manufacturing-friendly: mannitol, microcrystalline cellulose, croscarmellose sodium and magnesium stearate in the tablet core, with a hypromellose-based film coating containing titanium dioxide, talc and yellow iron oxide.[1]

The main commercial opportunity is not a radically differentiated excipient platform. It is improved dose flexibility, lower pill burden, more efficient global manufacturing, pediatric or dysphagia-friendly presentations, and formulation protection around delivery, stability and patient adherence.

What excipients are used in LYTGOBI tablets?

The LYTGOBI tablet uses a conventional immediate-release formulation.

Formulation element	Reported material	Likely function
Diluent	Mannitol	Bulking agent, palatability and mouthfeel
Diluent/compression aid	Microcrystalline cellulose	Tablet strength and compaction
Disintegrant	Croscarmellose sodium	Rapid tablet breakup
Lubricant	Magnesium stearate	Ejection and manufacturing lubrication
Film former	Hypromellose	Protective and cosmetic coating
Opacifier	Titanium dioxide	Appearance and light protection
Coating aid	Talc	Anti-tacking and coating process control
Colorant	Yellow iron oxide	Strength identification and product differentiation

The label identifies 4 mg and 12 mg film-coated tablets. The recommended dose is 20 mg once daily, which creates a dose-combination issue because the commercial strengths do not divide evenly into the standard dose.[1]

What does the LYTGOBI excipient system indicate about manufacturing?

The formulation is consistent with direct compression or a relatively simple dry-process tablet operation. Mannitol and microcrystalline cellulose provide a robust filler-compression combination, while croscarmellose sodium supports immediate release. Magnesium stearate is standard but requires control of blending time and concentration because over-lubrication can reduce tablet tensile strength and slow dissolution.

The system has four commercial advantages:

1. It uses globally available, low-cost excipients.
2. It avoids a specialized modified-release delivery platform.
3. It is compatible with standard high-speed solid-dose manufacturing.
4. It offers a relatively straightforward pathway for scale-up and technology transfer.

The main formulation risks are low-dose content uniformity, powder segregation, lubricant sensitivity, dissolution control and tablet-count burden.

Why is excipient selection important for futibatinib?

Futibatinib is administered at a 20 mg daily dose but is supplied in relatively small-strength tablets. The active pharmaceutical ingredient is potent, so the formulation must distribute a low quantity of drug uniformly throughout the blend. This makes the manufacturing process more sensitive to particle-size distribution, bulk density, electrostatic behavior and segregation than a high-dose tablet.

Mannitol and microcrystalline cellulose provide complementary compression properties. Mannitol can improve mouthfeel and reduce the perception of chalkiness, while microcrystalline cellulose supports tablet hardness. Croscarmellose sodium helps offset the risk that a highly compressed tablet will disintegrate slowly.

A formulation developer seeking to design an alternative product would need to demonstrate:

• Assay and content uniformity across the batch.
• Comparable dissolution across relevant pH conditions.
• Stability under heat and humidity.
• Controlled impurity formation.
• Consistent tablet hardness and friability.
• Adequate film-coating protection.
• Bioequivalence under fed and fasted conditions where required.

The conventional excipient system does not eliminate development work. It shifts the focus from novel delivery technology to process control and equivalence.

What formulation opportunities exist for LYTGOBI?

Reduced pill burden

The standard 20 mg dose can require multiple tablets. A 20 mg strength, if technically and commercially justified, could reduce tablet count. A 20 mg tablet would need to preserve dose flexibility for reductions and interruptions, which are common with FGFR inhibitors because of hyperphosphatemia, ocular toxicity, stomatitis and other adverse events.

A practical strength portfolio could include:

Strength strategy	Commercial benefit	Main risk
4 mg and 12 mg	Supports dose reduction and current regimen	Higher tablet count
4 mg, 8 mg and 12 mg	More granular titration	More SKUs and inventory
4 mg and 20 mg	Lower pill burden at starting dose	Less flexible combination dosing
Scored higher-strength tablet	Potentially supports dose adjustment	Uniformity, breakability and stability requirements
Orally disintegrating tablet	May help dysphagia and selected patients	Taste masking, moisture sensitivity and higher cost

A 20 mg tablet is the clearest commercial formulation opportunity, but it may not be the optimal regulatory or clinical strategy if dose reductions require frequent use of lower strengths.

Swallowability and dysphagia

Cancer patients may have difficulty swallowing tablets because of disease burden, treatment-related mucositis or concurrent medication load. A smaller, higher-potency tablet or an orally disintegrating dosage form could expand usability.

Potential excipient platforms include:

• Crospovidone or alternative superdisintegrants for rapid breakup.
• Mannitol-based orally disintegrating matrices.
• Taste-masking polymers or ion-exchange resins.
• Mini-tablets packaged as multiparticulate doses.
• Powder-for-suspension presentations for patients unable to swallow tablets.

An oral liquid would require particular attention to chemical stability, adsorption to packaging, dose uniformity, preservative selection and drug-excipient compatibility. A suspension may be more practical than a true solution if futibatinib has limited aqueous solubility, but it would introduce sedimentation and resuspension requirements.

Modified-release delivery

Modified release is a lower-priority opportunity. LYTGOBI is already dosed once daily, so extended release would have to produce a material clinical or adherence benefit. Potential objectives would include reducing peak-related toxicity, improving tolerability or maintaining exposure through a controlled plasma profile.

The development burden would include food-effect assessment, alcohol dose-dumping studies, in vitro-in vivo correlation, altered-release risk in gastrointestinal disease and a new bioequivalence package. A modified-release product would have stronger formulation differentiation but also a higher regulatory and manufacturing burden.

How does LYTGOBI compare with other FGFR inhibitors?

LYTGOBI competes primarily with pemigatinib, marketed as TRUSELTIQ, and futibatinib’s competitive position depends on molecular eligibility, treatment history, dosing convenience and toxicity management.

Product	Active ingredient	Main FGFR focus	Dosage form	Key formulation-commercial issue
LYTGOBI	Futibatinib	FGFR1-4, with clinical positioning in FGFR2-altered cholangiocarcinoma	Immediate-release tablets	Starting dose can require multiple tablets
TRUSELTIQ	Pemigatinib	FGFR1-3	Capsules	Capsule handling and dose flexibility
FGFR-directed investigational agents	Various	Often selective FGFR1-3 or FGFR2	Tablets or capsules	Differentiation may rely on selectivity, toxicity or convenience

Futibatinib is an irreversible inhibitor, while pemigatinib is a reversible inhibitor. That pharmacologic distinction may support clinical differentiation, but it does not by itself create an excipient advantage. For commercial purposes, the stronger formulation position will come from lower pill burden, fewer food restrictions, improved tolerability or more convenient dose adjustment.

What is the FDA regulatory status of LYTGOBI?

The FDA granted accelerated approval to LYTGOBI on September 30, 2022, for adults with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring an FGFR2 fusion or rearrangement.[2]

The approval was based on the TAS-120-101 study. The FDA label reports an objective response rate of 42%, with a median duration of response of 9.7 months in the relevant population.[1]

Regulatory item	Status
FDA product	LYTGOBI
Active ingredient	Futibatinib
Application	NDA 214801
Approval route	Accelerated approval
Initial U.S. approval	September 30, 2022
Indication	Previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma with FGFR2 fusion or rearrangement
Dose	20 mg orally once daily
Administration	With or without food
Main regulatory dependency	Confirmatory clinical evidence and continued benefit assessment

The label instructs patients to avoid grapefruit and grapefruit juice and to avoid strong or moderate CYP3A and P-glycoprotein inducers. These restrictions are not primarily excipient issues, but they affect the commercial value of any new formulation. A formulation that meaningfully reduces food, beverage or interaction restrictions would have a stronger market proposition than one that merely changes tablet appearance.[1]

What patents and exclusivity protect LYTGOBI?

LYTGOBI protection is expected to rely on multiple layers:

• Futibatinib compound patents.
• Crystalline or solid-state patents, where applicable.
• Pharmaceutical composition patents.
• Treatment-method patents for FGFR2-altered cholangiocarcinoma.
• Dosing and toxicity-management patents.
• Manufacturing-process patents.
• Regulatory exclusivity associated with the FDA approval.

The commercial importance of excipient patents depends on whether they claim a specific composition, dissolution profile, stability advantage, manufacturing process or clinical-use benefit. A broad claim covering mannitol, microcrystalline cellulose, croscarmellose sodium and magnesium stearate would be vulnerable if the combination is conventional and supported by extensive prior art. Narrower claims may be more defensible if they require defined ratios, particle-size ranges, dissolution limits, impurity controls or stability performance.

How strong is the LYTGOBI formulation patent estate?

The formulation estate is likely to be weaker than the compound estate if it relies only on standard excipients. Its strength would increase where claims cover:

• A defined futibatinib-to-excipient ratio.
• A narrow dissolution window.
• Reduced degradation under accelerated conditions.
• A specific polymorph or amorphous solid dispersion.
• A tablet architecture that improves content uniformity.
• A manufacturing process linked to critical quality attributes.
• A formulation that supports a clinically relevant dose reduction or administration advantage.

Generic or follow-on applicants could avoid a formulation patent by changing the filler, disintegrant, lubricant, coating system or manufacturing process, provided the resulting product meets bioequivalence and quality requirements.

When does LYTGOBI lose exclusivity?

The precise generic-entry date depends on the current Orange Book patent and exclusivity records, any patent-term adjustment or extension, pediatric extension, Paragraph IV litigation and settlement agreements. The first FDA approval date alone does not establish a reliable generic-entry date.

The principal U.S. entry routes are:

1. An ANDA with Paragraph IV certification against listed patents.
2. An ANDA filed after listed patent expiry.
3. A 505(b)(2) application for a clinically differentiated formulation.
4. A later-line product using an alternative strength, dosage form or administration method.

What Paragraph IV challenges could affect LYTGOBI?

A Paragraph IV applicant could challenge compound, formulation, method-of-use or manufacturing patents. The strongest generic strategy would usually target a non-infringing formulation while certifying against method-of-use claims that are difficult to avoid in a labeled product.

Risk factors include:

• A small molecule with conventional oral-tablet technology.
• A narrow patient population, which can reduce the commercial value of a complex generic challenge.
• Multiple dose reductions and tablet strengths, which may complicate product design.
• Method-of-use claims tied to biomarker-defined disease.
• Potential 30-month stays if litigation is timely filed after a Paragraph IV notice.

The commercial impact of a challenge depends on whether the challenger can obtain approval for the full indication, a carve-out indication or only a restricted label.

What manufacturing and IP barriers affect LYTGOBI competitors?

The active ingredient and analytical package are more important barriers than the excipients. A competing manufacturer must control:

• Futibatinib purity and related substances.
• Solid-state form and particle-size distribution.
• Low-dose blend uniformity.
• Tablet dissolution.
• Photostability and moisture sensitivity.
• Packaging interaction.
• Process-related impurities.
• Bioequivalence across strengths.

The conventional excipient profile reduces supply-chain barriers. Mannitol, microcrystalline cellulose, croscarmellose sodium and magnesium stearate are available from multiple global suppliers. The greater risk is supplier qualification and consistency rather than scarcity.

A manufacturer can create commercial value through dual sourcing, low-shear blending, continuous manufacturing, or a coating process that reduces weight gain and cycle time. Those advantages may improve gross margin without creating a durable legal moat.

What licensing and partnership opportunities exist for LYTGOBI?

The most credible licensing opportunities are adjacent to the product rather than centered on basic excipient supply.

Formulation and delivery partnerships

Potential partners include companies with capabilities in:

• Orally disintegrating tablets.
• Taste masking.
• Pediatric mini-tablets.
• Multiparticulate systems.
• High-potency low-dose manufacturing.
• Continuous oral-solid-dose production.
• Global packaging and serialization.

A partner with an established oncology distribution platform could also support regional expansion, especially in markets where intrahepatic cholangiocarcinoma diagnosis and FGFR testing are developing.

Diagnostic partnerships

Because the indication requires an FGFR2 fusion or rearrangement, companion or complementary diagnostic access is commercially important. Partnerships with molecular-testing providers can increase the number of patients identified as eligible for futibatinib therapy. This is more commercially material than marginal changes to the tablet excipients.

Combination-development partnerships

Futibatinib may have combination potential with chemotherapy, immunotherapy or other targeted agents, but any combination creates additional safety, interaction and formulation requirements. Co-packaged products could improve adherence, but fixed-dose combinations would require evidence that the dosing schedules, pharmacokinetics and dose modifications are compatible.

What revenue opportunities are linked to excipient strategy?

The largest revenue opportunities are indirect:

Opportunity	Revenue mechanism	Commercial priority
Lower-pill-burden strength	Better adherence and patient preference	High
Pediatric or dysphagia formulation	Expanded eligible-use population	Medium
Improved packaging and stability	Reduced waste and broader distribution	Medium
Lower-cost manufacturing	Margin expansion	High
Diagnostic partnerships	Higher patient identification	High
Modified release	Possible differentiation and lifecycle extension	Low to medium
Novel excipient platform	Potential formulation patent	Medium, but technically uncertain

LYTGOBI’s addressable market is constrained by the biomarker-defined population and the relatively small incidence of intrahepatic cholangiocarcinoma. Commercial growth therefore depends heavily on testing rates, treatment sequencing, geographic expansion and duration of therapy. Excipient reformulation can improve access and adherence, but it is unlikely to materially expand the market unless it solves a clinically meaningful administration problem.

What generic launch scenarios exist for LYTGOBI?

Scenario 1: Conventional immediate-release generic

A generic manufacturer uses standard excipients with a different qualitative or quantitative composition and demonstrates bioequivalence. This is the most likely long-term entry model if formulation patents are narrow.

Scenario 2: Paragraph IV challenge

A challenger disputes listed patents before expiry. The commercial value of the challenge depends on the remaining market size, expected litigation cost and whether the generic can secure a carve-out for protected method-of-use claims.

Scenario 3: 505(b)(2) formulation

A sponsor develops an orally disintegrating tablet, liquid, pediatric dosage form or modified-release product. This pathway could produce differentiated labeling but requires a stronger clinical and formulation rationale.

Scenario 4: Authorized generic or regional license

The originator or a commercial partner launches an authorized generic or licenses local manufacturing rights. This can preserve channel access while reducing exposure to independent generic competition.

Key Takeaways

• LYTGOBI uses a conventional immediate-release tablet excipient system built around mannitol, microcrystalline cellulose, croscarmellose sodium and magnesium stearate.[1]
• The primary formulation weakness is dose burden: the recommended 20 mg daily dose may require multiple tablets.
• A 20 mg tablet, improved strength architecture or dysphagia-friendly presentation offers the clearest lifecycle-management opportunities.
• Modified release is less attractive because LYTGOBI already has once-daily dosing.
• The strongest commercial lever is improved FGFR2 testing and patient identification, not excipient novelty.
• Standard excipients reduce manufacturing barriers and may make conventional generic development feasible after relevant protections expire.
• Formulation patent strength would depend on defined ratios, dissolution, stability, process controls or clinically meaningful delivery advantages.
• The FDA approval is accelerated and biomarker restricted, which limits the market but supports targeted diagnostic and licensing strategies.[2]

FAQs About LYTGOBI Formulation and Commercial Strategy

Can LYTGOBI tablets be crushed or split?

The FDA label instructs patients to swallow LYTGOBI tablets whole. Crushing, splitting or dispersing the tablets should not be treated as an approved administration method.[1]

Does LYTGOBI require a special food-effect formulation?

No. The label permits administration with or without food. Food and drug-interaction restrictions remain relevant to commercial positioning, particularly the avoidance of grapefruit and certain CYP3A or P-glycoprotein inducers.[1]

Would an orally disintegrating LYTGOBI tablet have regulatory value?

Yes, if it provides a clinically relevant advantage for dysphagia, adherence or dose administration. It would require control of taste, moisture, disintegration, stability and bioequivalence.

Are LYTGOBI’s excipients difficult to source?

No. The reported excipients are widely used pharmaceutical materials. The principal supply-chain issue is qualification and consistency for low-dose blend uniformity, not material scarcity.

Could a generic LYTGOBI use different excipients?

Yes. A generic generally can use a different excipient composition if it meets applicable quality, dissolution, stability and bioequivalence requirements and does not infringe enforceable formulation or process claims.

References

1. U.S. Food and Drug Administration. (2024). Lytgobi (futibatinib) prescribing information. Taiho Oncology, Inc.
2. U.S. Food and Drug Administration. (2022, September 30). FDA grants accelerated approval to futibatinib for advanced intrahepatic cholangiocarcinoma. FDA.
3. Goyal, L., Shi, L., Liu, L. V., Fece de la Cruz, F., Lennerz, J. K., Raghavan, S., Leschiner, G. D., et al. (2023). Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma. New England Journal of Medicine, 388(24), 2283-2295.
4. National Library of Medicine. (2024). DailyMed: Lytgobi-futibatinib tablet, film coated. U.S. National Library of Medicine.